Gallentes, Lyca L.
HRN: 19-25-64 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/22/2022
CEFUROXIME 500MG (TAB)
07/22/2022
07/29/2022
ORAL
500mg
Q12
S/P NSVD IUFD
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes